Praxis Precision Medicines Inc (PRAX)

Praxis Precision Medicines, Inc. is a clinical-stage biopharmaceutical company focused on therapies for central nervous system disorders linked to imbalance between neuronal excitation and inhibition in the United States. The company develops programs through its Cerebrum small-molecule platform for orally available precision treatments and its Solidus platform for antisense oligonucleotide discovery and development. Its pipeline includes ulixacaltamide, which is in NDA for essential tremor; relutrigine, also in NDA for SCN2A- and SCN8A-developmental and epileptic encephalopathies and in Phase 3 for broader DEEs; vormatrigine, in Phase 3 for adjunctive focal epilepsy and Phase 2 for monotherapy focal epilepsy; and Elsunersen, a clinical-stage ASO in Phase 3 for SCN2A-DEE. The company also has earlier-stage programs including PRAX-020, PRAX-080, PRAX-090 and PRAX-100, and it maintains collaboration and license agreements with RogCon Inc. and Ionis Pharmaceuticals. Founded in 2015 and headquartered in Boston, Massachusetts, Praxis Precision Medicines previously operated as EpiPM Therapeutics, Inc.

Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.